Ravi Kamepalli, MD
Infectious Disease · Lagrange, GANPI 1669464681
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.2% of the total across 91 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $763, 2.5 times the $307 reported in 2019.
Across 91 payments — averaging $28.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$467
- Kerecis Limited$352
- Pfizer$196
- AstraZeneca$169
- Smith+Nephew$143
- Amgen$137
- plus $1K from 30 others
Across 224 payments — averaging $225.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$30K
- Novo Nordisk AS$14K
- Astellas Pharma Global Development$4K
- Ferring Pharmaceuticals AS$2K
- Merck$2K
- Novo Nordisk$50
What the payments were for
- Food & beverage$2,45294%
- Education$1506%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 15 | $467 |
| Kerecis Limited | 7 | $352 |
| Pfizer | 2 | $196 |
| AstraZeneca | 3 | $169 |
| Smith+Nephew | 6 | $143 |
| Amgen(2 entities) | 7 | $137 |
| Astellas Pharma US Inc | 5 | $135 |
| Ascensia Diabetes Care US Inc. | 1 | $112 |
| Reprise Biomedical, Inc. | 9 | $104 |
| Ferring Pharmaceuticals Inc. | 5 | $95 |
| Zealand Pharma US, Inc. | 1 | $65 |
| Abbott | 1 | $52 |
| Melinta Therapeutics, LLC | 2 | $48 |
| Corcept Therapeutics | 2 | $41 |
| Imbed Biosciences Inc. | 1 | $37 |
| Stryker | 1 | $36 |
| EMD Serono, Inc. | 1 | $35 |
| Bone Support Inc. | 1 | $33 |
| Scpharmaceuticals Inc. | 1 | $33 |
| Novo Nordisk | 1 | $32 |
| La Jolla Pharmaceutical Company | 2 | $31 |
| Medtronic | 1 | $27 |
| Paratek Pharmaceuticals, Inc. | 1 | $24 |
| Cvrx, Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $22 |
| Polymedics Innovations Inc. | 1 | $18 |
| Mimedx Group, Inc. | 1 | $18 |
| Aroa Biosurgery Incorporated | 1 | $18 |
| Reddress USA, Inc. | 1 | $18 |
| AbbVie | 1 | $15 |
| Biowound Solutions, Inc. | 3 | $14 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $12 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
| Dexcom, Inc. | 1 | $12 |
| Convatec Inc. | 1 | $11 |
| Lifenet Health | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerecis SurgiClose$1,080
- Kerecis GraftGuide$270
- ABRYSVO$136
How this compares
$2,602 in reported general payments places this provider in the 65th percentile of 260 infectious disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KrystexxaPegloticase | 15 | $572,109 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 22 | $92,920 |
| Daptomycin | 79 | $42,694 |
| JardianceEmpagliflozin | 15 | $18,354 |
| ErtapenemErtapenem Sodium | 35 | $13,822 |
| Vancomycin Hcl | 73 | $12,180 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 28 | $8,727 |
| CeftriaxoneCeftriaxone Sodium | 96 | $5,103 |
| FarxigaDapagliflozin Propanediol | 13 | $4,786 |
| Meropenem | 12 | $4,395 |
| Cefepime Hcl | 11 | $3,268 |
| Doxycycline Hyclate | 91 | $1,496 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 71 | $1,254 |
| Ampicillin-SulbactamAmpicillin Sod/Sulbactam Sod | 11 | $914 |
| Ciprofloxacin Hcl | 65 | $778 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenKrystexxa | $137 | $572,10915 claims |
| AstraZenecaFarxiga | $169 | $4,78613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 260 infectious disease providers in Georgia.
Other infectious disease in Lagrange
- Andrew DoldDacula$1.1M
- Zandraetta Tims-CookAtlanta$848K
- Jeffrey StephensMacon$356K
- Jose VazquezAugusta$335K
- Larry AndersonAtlanta$300K
- Quintin RobinsonAtlanta$270K
- James McMillenAtlanta$177K
- Leandro MenaAtlanta$141K
- Cheryl NewmanAugusta$128K
- Colleen KraftAtlanta$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.